How much does stem cell treatment for Degenerative Disc Disease cost?
At Stem Cell Mexico, stem cell treatment for degenerative disc disease typically costs between $4,500 and $6,500 USD.

The final price depends on how many spinal levels are treated, whether the lumbar spine, the cervical spine or both are involved, the number of cells recommended per level, the imaging guidance required (fluoroscopy is used for spinal procedures), whether sedation and an IV infusion are included, and the length of your medical observation. Your complete cost is confirmed in writing after a medical evaluation and before any deposit, and only the items listed in your quote are included.
Spine treatments cost more than most joint injections because they require more precise image guidance, a hospital-level procedure environment and often more than one target. Below we explain what you are paying for, how the treatment works and what current evidence shows, so you can make an informed decision.
What degenerative disc disease is
Intervertebral discs sit between the vertebrae and act as shock absorbers. Each disc has a tough outer ring (the annulus fibrosus) and a gel-like center (the nucleus pulposus). With age, repetitive load, injury and genetics, discs lose water, height and elasticity. This process is called disc degeneration.
"Degenerative disc disease" is not exactly a disease; it describes degeneration that is associated with pain or other symptoms. It can lead to:
- Discogenic pain, coming from the disc itself, often felt as deep low back or neck pain that worsens with sitting or bending.
- Disc bulges or herniations, which can compress nerves and cause sciatica or arm pain with numbness or tingling.
- Facet joint and sacroiliac joint overload, adding other sources of pain.
- Spinal canal or foraminal narrowing in more advanced cases.
Many people have degenerated discs on MRI without pain, which is why an MRI alone is not enough. The doctor has to connect your imaging with your symptoms and physical examination.
What the price usually includes
A typical spinal plan at our clinic includes:
- Medical evaluation with the doctor and stem cell specialist, reviewing your MRI (no older than three months), prior treatments and symptoms.
- Pre-treatment laboratory testing: complete blood count, metabolic panel, urinalysis and tumor markers.
- Allogeneic mesenchymal stromal cells (MSCs) from donated umbilical cord tissue, prepared for your scheduled date.
- Fluoroscopy-guided injections performed in a hospital setting, so the needle placement can be confirmed in real time.
- Platelet-rich plasma (PRP) from your own blood when indicated, and sedation for comfort and precision.
- Medical observation, often including an overnight stay, plus ground transportation and follow-up.
Flights, extra hotel nights and companion lodging are usually separate. If you need an MRI on arrival, it is added to the quote.
Why the price ranges from $4,500 to $6,500
Number of levels and regions
Treating one lumbar level (for example, L4-L5) is very different from treating several lumbar levels plus the cervical spine. Each additional level adds cells, procedure time and fluoroscopy work.
Target structures
Depending on the source of your pain, the plan may include the disc itself (intradiscal), the facet joints, the sacroiliac joints or surrounding soft tissues. Your doctor should explain which structures will be treated and why.
Cell dose
Doses for each level are adjusted to the size of the target and the degree of degeneration. As in joints, more cells are not automatically better, because excessive volume in a confined disc space can increase post-procedure pain.
Add-ons
An IV infusion for systemic anti-inflammatory support, NAD+ therapy or extended monitoring may be part of some plans and influence the total.
How the treatment works
Discs have very limited blood supply, which is one reason they heal poorly. Mesenchymal stromal cells are studied in disc disease because they may:
- Reduce inflammation inside and around the degenerated disc, a major contributor to discogenic pain.
- Release trophic factors that support the survival of remaining disc cells and the production of extracellular matrix, including proteoglycans that help the disc hold water.
- Modulate pain signaling by changing the inflammatory environment around nerve endings.
Under fluoroscopic guidance, the specialist places the cells precisely at the target. PRP may be added to provide additional growth factors. Most patients go home after observation, with soreness for several days.
What the evidence says
Current standard care: The UK's National Institute for Health and Care Excellence (NICE) guideline on low back pain and sciatica (NG59) recommends exercise, manual therapy as part of a treatment package, psychological approaches when appropriate, and selected medications. It does not include cell therapy. Surgery is reserved for specific situations, such as persistent nerve compression.
Growing randomized evidence: A 2026 systematic review and meta-analysis published in the Asian Spine Journal analyzed seven randomized controlled trials with 594 patients with chronic low back pain from degenerative disc disease. Intradiscal MSC injection was associated with significantly greater reductions in pain than control, with benefits that became more evident at 12 to 36 months, along with improvements in disability scores (Oswestry Disability Index). Adverse events, serious complications and discontinuations were similar between MSC and control groups.
Broader clinical review: A systematic review of clinical studies on mesenchymal stromal cells for discogenic low back pain reached a similar conclusion: results are encouraging and safety is generally favorable, but studies differ widely in cell type (bone marrow, adipose, umbilical cord), dose, carrier and patient selection, and more large, high-quality trials are needed.
What this means for you: Regenerative therapy for disc disease has moved beyond small pilot studies into randomized trials with moderate-sized groups. The evidence suggests that some patients experience meaningful, durable pain relief, but responses vary, and it does not reverse degeneration on imaging in a predictable way.
Regulatory context
No stem cell product is currently approved by the FDA for degenerative disc disease. In Mexico, cell therapies are regulated by COFEPRIS, and fluoroscopy-guided spinal procedures should be performed in an appropriate hospital setting. Ask where your procedure will take place and who will perform it.
Who may be a candidate
Good candidates typically have:
- Chronic back or neck pain (usually more than six months) linked to disc degeneration on a recent MRI.
- Inadequate relief from physical therapy, medications or injections.
- Mild to moderate degeneration, with some disc height preserved.
- No severe spinal instability, progressive neurological deficit or cauda equina symptoms, which require urgent surgical evaluation.
- No active infection, uncontrolled bleeding disorder or cancer history within the past five years.
Patients who have had spinal surgery, including fusion or disc replacement, may still be evaluated, but the plan has to account for the altered anatomy.
What results patients commonly ask about
When will I feel better? Post-procedure soreness for a few days to two weeks is common. Many patients describe gradual improvement over two to three months, with continued changes up to a year.
Will the MRI look different? Sometimes; imaging changes do not always match how you feel, so pain and function are the main measures. Pain and function are more meaningful measures than imaging appearance.
Could I still need surgery? Possibly. Regenerative treatment can help some people delay or avoid surgery, but it cannot fix severe mechanical compression or instability.
What can affect outcomes
- Number and severity of degenerated levels.
- Whether pain comes from the disc or from nerves, facets or muscles.
- Body weight, smoking (which impairs disc nutrition) and physical conditioning.
- Following the post-treatment plan and starting guided core and mobility exercises.
Preparing for a spinal procedure
Preparation helps both safety and results. Send your most recent MRI images and report, along with any operative reports if you have had spine surgery. About seven days before treatment, you will usually be asked to pause anti-inflammatory painkillers such as ibuprofen, naproxen or aspirin, unless a doctor has prescribed aspirin for heart protection, in which case the team will advise you; paracetamol (acetaminophen) and tramadol are generally allowed for pain. Natural anti-inflammatories like omega 3, turmeric and ginger are typically paused five days before. Tell the team if you take blood thinners, because spinal injections require special planning. After treatment, plan a few quiet days, avoid lifting and long drives, and begin gentle, guided movement as instructed.
Risks and limitations
Spinal injections carry procedure-related risks: temporary pain flare, headache, nerve irritation, bleeding and, rarely, disc infection (discitis). Fluoroscopic guidance and sterile technique reduce these risks. Serious adverse events have been uncommon in trials. The main limitation is variability: not every patient improves, and the degree of improvement differs.
Questions to ask during your evaluation
- Which levels and structures do you plan to treat, and why those?
- Will the procedure use fluoroscopic guidance, and where will it be performed?
- How many cells per level, and what evidence supports that dose?
- What is included in my quote, and what could change it?
- What rehabilitation plan should I follow afterward?
Bottom line
Stem cell treatment for degenerative disc disease at Stem Cell Mexico generally ranges from $4,500 to $6,500 USD, based on the number of levels, regions and components involved. Randomized trials show encouraging reductions in pain and disability with a favorable safety profile, though results vary and the field continues to mature. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your spine, symptoms and medical history, and gives you a written quote before you decide.
References
- NICE guideline NG59: Low back pain and sciatica in over 16s, assessment and management (opens in a new tab)
- Rahyussalim et al. Intradiscal mesenchymal stem cell therapy for degenerative disc disease: a systematic review and meta-analysis of randomized trials. Asian Spine Journal, 2026 (opens in a new tab)
- Mesenchymal stromal cells for the treatment of discogenic low back pain: a systematic review of clinical studies (PMC) (opens in a new tab)
